Table 2 SARS-CoV-2 IgG titers between/among groups with different characteristics
From: Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
SARS-CoV-2 IgG titers (log BAU/mL, mean (SD)) | P value | |
|---|---|---|
Age, years | 0.49 | |
< 60 (n = 390) | 3.12 (0.40) | |
≧ 60 (n = 434) | 3.10 (0.51) | |
Gender | 0.02 | |
Male (n = 401) | 3.07 (0.48) | |
Female (n = 423) | 3.15 (0.45) | |
BMI | 0.03 | |
< 24 kg/m2 (n = 387) | 3.07 (0.48) | |
≧ 24 kg/m2 (n = 409) | 3.14 (0.45) | |
Dyslipidemia | 0.36 | |
Yes (n = 128) | 3.07 (0.52) | |
No (n = 694) | 3.11 (0.45) | |
Hypertension | 0.71 | |
Yes (n = 278) | 3.10 (0.45) | |
No (n = 544) | 3.12 (0.49) | |
Diabetes | 0.64 | |
Yes (n = 147) | 3.09 (0.53) | |
No (n = 675) | 3.11 (0.45) | |
Chronic kidney disease |  < 0.001 | |
Yes (n = 166) | 2.97 (0.53) | |
No (n = 656) | 3.14 (0.44) | |
Chronic liver disease* | 0.12 | |
Yes (n = 552) | 3.13 (0.45) | |
No (n = 270) | 3.07 (0.49) | |
History of malignancy | 0.25 | |
Yes (n = 101) | 3.04 (0.58) | |
No (n = 721) | 3.11 (0.45) | |
Charlson comorbidity index |  < 0.001 (CCI 0–1 vs. 2–3 vs. ≧ 4) | |
0 (n = 130) | 3.14 (0.38) | |
1 (n = 305) | 3.14 (0.40) | |
2 (n = 146) | 3.09 (0.48) | |
3 (n = 112) | 3.12 (0.50) | |
≧ 4 (n = 131) | 3.00 (0.56) |